Microbiological and clinical characteristics of Acinetobacter baumannii bacteremia: Implications of sequence type for prognosis - 01/02/19
Highlights |
• | Sequence type 2 Acinetobacter baumannii strains were more multidrug resistant than non-sequence type 2 strains. |
• | Bacteremia caused by A. baumannii sequence type 2 was associated with greater disease severity. |
• | Sequence type 2 strains were associated with higher rates of mortality. |
Summary |
Objectives |
Acinetobacter baumannii (Ab) is an important cause of healthcare-associated infections. Multilocus sequence typing (MLST) provides a highly discriminative typing method. We aimed to determine the clinical impact of Ab sequence types (ST) in patients with bloodstream infection (BSI).
Methods |
Patients with Ab-BSI were followed prospectively from 2009 to 2014. We randomly selected one-third of non-duplicate bacteremic isolates for MLST and correlated the Ab ST with the clinical course. The primary outcome was all-cause in-hospital mortality.
Results |
We enrolled 148 patients. Seventy-seven (52.0%) of the isolates were ST2. Patients with ST2-BSI were less likely to be treated with appropriate empirical antimicrobial agents (31.1% vs. 60.6%; P < 0.001). They had greater mortality (66.2% vs. 40.8%; P = 0.003) than patients with non-ST2-BSI. In the multivariable analysis, ST2 independently predicted greater severity of infection (Pitt bacteremia score) (adjusted odds ratio (aOR), 3.38; 95% confidence interval (CI), 1.75–6.54; P < 0.001). Mediated by a higher Pitt bacteremia score (Sobel test P < 0.001), ST2 is an independent prognostic factor that predict mortality (aOR, 2.34; 95% CI, 1.07–5.11; P = 0.03).
Conclusions |
ST2 was associated with high rates of inappropriate antimicrobial therapy, severe infection and mortality. Further studies are needed to confirm our findings and explore the potential of role of the virulence.
Le texte complet de cet article est disponible en PDF.Keywords : Acinetobacter baumannii, Bacteremia, Multilocus sequence typing, Outcome, Molecular epidemiology
Plan
Vol 78 - N° 2
P. 106-112 - février 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?